Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (SRPT) Posts Smaller Q1 Loss, Revs Miss

May 6, 2020 4:44 PM EDT

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.04), $0.83 better than the analyst estimate of ($1.87). Revenue for the quarter came in at $100.4 million versus the consensus estimate of $119.15 million.

I am proud to report that with our typical sense of urgency the Sarepta team rapidly adapted to the challenges and obstacles posed by the COVID-19 pandemic, assessing and minimizing potential impacts, working to protect our patients, protecting our facility-dependent workers, and driving our mission forward. In mid-March, we smoothly transitioned the majority of our employees to work-from-home status and, for the approximately 10% of our workforce that... More